These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11521729)

  • 1. The role of overexpressed HER2 in transformation.
    Neve RM; Lane HA; Hynes NE
    Ann Oncol; 2001; 12 Suppl 1():S9-13. PubMed ID: 11521729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The basic biology of HER2.
    Rubin I; Yarden Y
    Ann Oncol; 2001; 12 Suppl 1():S3-8. PubMed ID: 11521719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
    Albanell J; Codony J; Rovira A; Mellado B; Gascón P
    Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HER2: recent developments and future directions for breast cancer patients.
    Wang SC; Zhang L; Hortobagyi GN; Hung MC
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology of HER2 and its importance in breast cancer.
    Yarden Y
    Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER2 in other tumor types.
    Scholl S; Beuzeboc P; Pouillart P
    Ann Oncol; 2001; 12 Suppl 1():S81-7. PubMed ID: 11521727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Pal SK; Pegram M
    Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.
    Stern DF
    Breast Cancer Res; 2000; 2(3):176-83. PubMed ID: 11250707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From HER2 to herceptin.
    Mokbel K; Hassanally D
    Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
    Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
    Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
    Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
    Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the biologic and clinical complexities of HER2.
    Park JW; Neve RM; Szollosi J; Benz CC
    Clin Breast Cancer; 2008 Oct; 8(5):392-401. PubMed ID: 18952552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.